OGN | tickerfilter.com

Fundamental analysis

50%

Profitability 49%

Dept financing 41%

Liquidity 63%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.45%

1 Month

-15.19%

3 Months

-3.78%

6 Months

-33.82%

1 Year

-52.46%

2 Year

-55.62%

Key data

Stock price

$6.87

P/E Ratio

9.94

DAY RANGE

$6.83 - $7.06

EPS

$0.59

52 WEEK RANGE

$6.18 - $16.08

52 WEEK CHANGE

-$53.77

MARKET CAP

1.859 B

YIELD

4.75%

SHARES OUTSTANDING

260.316 M

DIVIDEND

$0.02

EX-DIVIDEND DATE

02-23-2026

NEXT EARNINGS DATE

08-05-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$3,829,151

AVERAGE 30 VOLUME

$4,542,406

Company detail

CEO: Kevin Ali
Region: US
Website: organon.com
Employees: 10,000
IPO year: 2021

Issue type:
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies.

OGN - Organon & Co.